Nektar Therapeutics (NKTR)
73.69
-0.33
(-0.45%)
USD |
NASDAQ |
Aug 24, 16:00
74.20
+0.51
(+0.69%)
After-Hours: 07:10
Nektar Therapeutics Enterprise Value : 1.967B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 1.967B |
| August 21, 2026 | 1.978B |
| August 20, 2026 | 1.995B |
| August 19, 2026 | 2.048B |
| August 18, 2026 | 1.965B |
| August 17, 2026 | 1.932B |
| August 14, 2026 | 1.944B |
| August 13, 2026 | 2.043B |
| August 12, 2026 | 2.046B |
| August 11, 2026 | 2.028B |
| August 10, 2026 | 2.007B |
| August 07, 2026 | 2.062B |
| August 06, 2026 | 1.958B |
| August 05, 2026 | 1.946B |
| August 04, 2026 | 1.935B |
| August 03, 2026 | 1.861B |
| July 31, 2026 | 1.864B |
| July 30, 2026 | 1.890B |
| July 29, 2026 | 1.864B |
| July 28, 2026 | 1.867B |
| July 27, 2026 | 1.887B |
| July 24, 2026 | 1.865B |
| July 23, 2026 | 1.819B |
| July 22, 2026 | 1.817B |
| July 21, 2026 | 1.795B |
| Date | Value |
|---|---|
| July 20, 2026 | 1.665B |
| July 17, 2026 | 1.781B |
| July 16, 2026 | 1.740B |
| July 15, 2026 | 1.783B |
| July 14, 2026 | 1.744B |
| July 13, 2026 | 1.783B |
| July 10, 2026 | 1.853B |
| July 09, 2026 | 1.940B |
| July 08, 2026 | 1.906B |
| July 07, 2026 | 2.008B |
| July 06, 2026 | 1.948B |
| July 02, 2026 | 1.876B |
| July 01, 2026 | 1.649B |
| June 30, 2026 | 1.834B |
| June 29, 2026 | 907.40M |
| June 26, 2026 | 871.94M |
| June 25, 2026 | 838.92M |
| June 24, 2026 | 896.19M |
| June 23, 2026 | 933.89M |
| June 22, 2026 | 913.72M |
| June 18, 2026 | 817.53M |
| June 17, 2026 | 816.30M |
| June 16, 2026 | 803.06M |
| June 15, 2026 | 820.89M |
| June 12, 2026 | 784.92M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Elite Pharmaceuticals, Inc. | 278.03M |
| Daré Bioscience, Inc. | 6.305M |
| Aclaris Therapeutics, Inc. | 792.59M |
| Eton Pharmaceuticals, Inc. | 1.825B |
| Journey Medical Corp. | 218.67M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -40.62M |
| Revenue (Quarterly) | 10.13M |
| Total Expenses (Quarterly) | 50.75M |
| EPS Diluted (Quarterly) | -1.229 |
| Gross Profit Margin (Quarterly) | 98.46% |
| Profit Margin (Quarterly) | -401.0% |
| Earnings Yield | -9.09% |
| Normalized Earnings Yield | -8.632 |